<DOC>
	<DOCNO>NCT00926224</DOCNO>
	<brief_summary>The main objective study evaluate diagnostic performance XL probe estimate degree liver fibrosis/cirrhosis obese patient &gt; 28 kg/m² various liver disease patient chronic liver disease schedule liver biopsy .</brief_summary>
	<brief_title>Fibroscan® Its Dedicated Probes Efficiency Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Patient least 18 year age Patient able give write informed consent form Patient BMI superior equal 28kg/m² Patient schedule liver biopsy within 1 month enrollment liver biopsy perform within 6 month enrollment . Patient abdominal ultrasound technically possible Unable unwilling provide write informed consent Confirmed diagnosis and/or history malignancy , terminal disease Patients clinical ascites Pregnant woman Patient BMI &lt; 28 kg/m² Patients active implantable medical device ( pacemaker defibrillator ) Transplanted patient patient heart disease Refusal undergo liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Adult patient chronic liver disease schedule liver biopsy BMI superior equal 28 kg/m²</keyword>
</DOC>